Kristin Haag

Aug 29, 2023 | acrjournals.onlinelibrary.wiley.com | Michelle Petri |Daniel Joyce |Kristin Haag |Andrea Fava

INTRODUCTION Both systemic lupus erythematosus (SLE) itself and the use of some immunosuppressants may impact the risk of COVID-19 (1-3). In particular, corticosteroids and B cell–depleting biologics such as rituximab impair vaccine response (4-6). SLE increases the risk of severe COVID-19 (hospitalization, intensive care unit stay, or intubation) both before and after vaccination (7).

Aug 17, 2023 | acrjournals.onlinelibrary.wiley.com | Michelle Petri |Daniel Joyce |Kristin Haag |Andrea Fava

No abstract is available for this article. Supporting Information Filename Description acr25109-sup-0001-Disclosureform.pdfPDF document, 1.8 MB Disclosure Form References 1, , , et al. Effect of systemic lupus erythematosus and immunosuppressive agents on COVID-19 vaccination antibody response. Arthritis Care Res (Hoboken) doi: https://doi.org/10.1002/acr.25094. 2023. E-pub ahead of print. 2, . COVID-19 in immunocompromised hosts: what we know so far.

Mar 3, 2023 | onlinelibrary.wiley.com | Michelle Petri |Daniel Joyce |Kristin Haag |Andrea Fava

Reply This article has been accepted for publication and undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process, which may lead to differences between this version and the Version of Record. Please cite this article as doi: 10.1002/acr.25109. No abstract is available for this article.